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ABSTRACT Actinic keratosis (AK) negatively influences patient qual-
ity of life as measured by the disease-specific Actinic Keratosis Quality 
of Life (AKQoL) questionnaire. The quality of life in Australian patients 
was significantly less affected than in Danish patients. We hypothesize 
that general factors such as public awareness and cultural connota-
tions of AK, may influence the impact of AK on quality of life (QoL). 
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INTRODUCTION
Actinic keratosis (AK) is a common disease with a 
prevalence of around 3% of the population. The preva-
lence increases with age and is dependent on geog-
raphy, being higher in countries with higher UV-expo-
sure (1,2). It is often considered a premalignant skin 
condition which may develop into non-melanoma 
skin cancer (NMSC) if left untreated, although it is ac-
knowledged that the transformation rate is low (3). The 
incidence of both AK and NMSC appears to be rising, 
contributing to the overall burden of these diseases on 
society (4). AK has a negative effect on dermatology 
and disease-specific quality of life (QoL) (5,6). 
The risk of AK and NMSC is greater in Australia 
than in other countries such as Denmark, most likely 
due to differences in ultraviolet (UV) burden and as-
sociated exposure. The overall result is reflected in the 
reported prevalence rates of AK/NMSC, although sig-
nificant under-reporting of AK is suspected to occur 
in all countries. The number of people with sun dam-
age and prevalence of AK/NMSC in Australia is one of 
the highest in the world, with over 434 000 people 
(1.9% of the 22.7 million inhabitants) being treated 
for one or more NMSC in Australia annually (7). In 
comparison, 13 794 patients (2.4% of the 5.6 million 
inhabitants) were treated for NMSC in Denmark (from 
the Clinical Database of Non-Melanoma Skin Cancer 
in Dermatology Practice 2013 - A. Lamberg, Aarhus 
Univeristy Hospital Denmark). We therefore hypothe-
sized that there is a difference in disease-specific QoL 
when comparing Australian and Danish patients with 
AK due to differences in climate, NMSC prevalence, 
and cultural connotations of AK. 
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Therefore, our objective was to explore this hy-
pothesis by assessing the disease-specific QoL in 
patients with AK in Australia and compare it to the 
disease-specific QoL in patients with AK in Denmark 
in a pilot study. 
To the best of the authors’ knowledge no such 
study has been previously performed.
PATIENTS AND METHODS
The newly developed and validated disease-spe-
cific questionnaire Actinic Keratosis Quality of Life 
(AKQoL) was used to asses QoL (6,8). AKQoL has three 
domains covering emotion, function, and control and 
one single global item. It includes 9 questions in total, 
each question with 4 options, scored 0-3 with a total 
maximum score of 27; the higher the score the higher 
the impairment of QoL.
Generic QoL tools such as the EQ5D, or skin-spe-
cific QoL tools such as the Dermatology Life Qual-
ity Index (DLQI), only poorly reflect morbidity in AK/
NMSC and were therefore not included in the study. 
To the best of our knowledge no other AK-specific 
QoL instrument exists.
The project was approved by the national Bellber-
ry ethical committee in Australia, and all participants 
signed an informed consent form. Questionnaire-
based studies do not require ethical committee ap-
proval in Denmark.
Patients were recruited according to their health-
care-seeking behavior, i.e. at comparable institutions 
in the two countries. In consequence, no direct com-
parison regarding the number, location or treatment 
of AK was made. The English translated and con-
tent-validated AKQoL questionnaire was mailed in 
stamped addressed envelopes to 92 patients with AK 
attending the Academic Dermatology Practice affili-
ated with the University of NSW, in Kogarah, Sydney, 
Australia in April 2013. The patients with AK were 
identified by the payment code for cryo-treatment of 
more than 10 AKs, as there is no code for treating less 
than 10 AKs in Australia.
The same questionnaire was handed out to 105 
outpatients with AK during their visit at different Der-
matology Practices in Region Zealand in Denmark 
during the period from November 2005 to February 
2006. The patients either filled out the questionnaire 
at the clinic or returned the filled out questionnaire 
by post from home.
The Wilcoxon test was used to compare mean 
AKQoL scores, and the Chi-square test was used to 
compare the sex-distribution between the two coun-
tries. Univariable and multivariable linear regression 
analyses were undertaken to investigate the differ-
ence in the total AKQoL score between the two coun-
tries. Age, sex, and the country of origin were chosen 
as potentially important variables. The analyses were 
performed in SAS® software (SAS Institute Inc., Cary, 
NC, USA) version 9.2 and in R, version 2.15.2 (R Devel-
opment Core Team, 2013).
RESULTS
A total of 29 Australian patients with AK respond-
ed yielding a participant rate of 31.5%.
A total of 105 Danish patients with AK responded 
yielding a participant rate of 100%. 
The mean age and sex distribution for the Aus-
tralian and Danish patients with AK can be found in 
Table 1.
The mean AKQoL scores for Australian and Danish 
patients with AK were 6.48 (standard deviation (SD) 
±5.28) and 9.51 (SD ±4.96), respectively, yielding a 
statistically significant mean difference of 3.03 points 
(95% confidence interval (CI) 0.94 – -5.12, P=0.0047) 
(Table 2). After adjusting the results for age and sex, 
the difference between the Danish and Australian 
Table 1. Mean age and sex distribution in Australian and Danish patients with AK
Australian patients with AK n=29 Danish patients with AK n=105
Age (mean years (range)) 69.29 (48-95) 68.15 (41-86)







Total (mean ± SD)
6.48 (SD ±5.28) 9.51 (SD ±4.96)
Emotion domain 2.03 (SD ±2.02) 3.31 (SD ±2.14)
Function domain 2.45 (SD ±1.88) 3.83 (SD ±1.82)
Control domain 1.69 (SD ±1.63) 1.82 (SD ±1.82)
Single item 3 0.31 (SD ±0.71) 0.55 (SD ±0.68)
*AK: actinic keratosis; AKQoL: Actinic Keratosis Quality of Life; SD: standard deviation
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patients in the total AKQoL score became slightly 
smaller; nonetheless, the difference remained statis-
tically significant (2.51, 95% CI 0.13 – 4.89, P=0.039) 
(Table 2). The Danish population had a significantly 
higher score in the emotion domain (P=0.0019), the 
function domain (P=0.0001), and for the single item 
(P=0.0142) but a non-significantly higher score in the 
control domain (P=0.2959) (Table 1).
DISCUSSION
The results of this crude survey indicate that pa-
tients with AK have impaired QoL in both countries, 
albeit at different levels when assessed by the AKQoL. 
AK appears to be associated with a lower disease-
specific QoL in Denmark compared with Australia. 
Several circumstances may influence this. The high 
prevalence and subsequently increased media cov-
erage of sun damage in Australia may lead to “ac-
climatization” of the Australian public, i.e. making 
them care less about sun damage. Alternatively, the 
increased awareness of skin cancer in Australia may 
change the perspective of patients, i.e. being relieved 
to “only” have AKs rather than NMSC. Further cultural 
connotations and practical management may play a 
part. The fact that Australian patients had >10 lesions 
and Danish patients could have far fewer lesions may 
also have contributed to this possible Australian “de-
sensitization”. Similarly, cryotherapy may have been 
more commonly used in Australian patients, indicat-
ing that the group was less cosmetically aware.
To the best of our knowledge no other studies 
have assessed the difference between QoL in two cul-
turally and geographically different AK populations. In 
fact very few studies have assessed the impact of AK 
on patient QoL at all. The definition of the study pop-
ulations according to their health-seeking-behavior is 
an obvious weakness of the study. Other weaknesses 
are the lack of clinical detail. A cross-sectional study 
using Skindex-29 and 6 keratinocyte carcinoma-spe-
cific questionnaires found that higher AK counts and 
past use of topical 5-fluorouracil (5-FU) were predic-
tors of worse QoL in an American veterans’ group 
(10). In contrast, a longitudinal study from the same 
group reported that increased AK counts did not in-
fluence the QoL (5). The absence of clinical detail may 
therefore be of lesser importance than expected. The 
time-lapse between the data-gathering may also be 
of importance as it may have influenced the percep-
tions of both patient group as well as treatment op-
portunities. Finally, the low participation rate among 
Australian patients may be seen both as a problem 
but also as suggesting that they consider the prob-
lem less important as also reflected by the AKQoL 
score. Such an interpretation is supported by qualita-
tive studies that have identified significant emotional 
QoL issues with AK (8,9). The potential influence of 
physical comorbidities remains unexplored.
Obviously, the exploratory nature of this small 
study precludes nation-wide generalization of the 
results, which are nevertheless of interest in view of 
the increasing attention being given to AK as a skin 
disease.
The major strength of the study is the use of a vali-
dated disease-specific QoL questionnaire. The major 
limitation of this study is the small number of Aus-
tralian patients with AK, yielding a low participation 
rate. It is possible that because the ethics commit-
tee in Australia insisted upon a consent form being 
signed as well as the questionnaire, this extra effort 
may have been off-putting. Patients sent question-
naires via mail rather than being approached in per-
son are also less likely to have high response rates. 
However, this may be speculated to reflect the fact 
that Australian patients with AK are not as concerned 
with their skin condition as Danish patients. There 
was a slight non-significant difference in the sex dis-
tribution between the Australian and Danish patients 
with (P=0.1266). 
Table 2. Results of the univariable and multivariable linear regression analyses with the total AKQoL score as 
the dependent variable
Univariable analysis Multivariable analysis
Changes in total AKQoL 
(95% CI)




Danish AK patients 
Reference
3.03 (+0.94 – 5.12)
0.0047
Reference





-2.35 (-0.51 – -4.19)
0.013
Age (per 1 year increment) -0.03 (-0.11 – 0.05) 0.50
*AK: actinic keratosis; AKQoL: Actinic Keratosis Quality of Life; CI: confidence interval
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CONCLUSION
Danish patients with AK have a lower disease-spe-
cific QoL when compared with Australian patients 
with AK. We hypothesize that climate differences as 
well as different degrees of public awareness and 
cultural connotations influenced the impact of AK on 
QoL.
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